ArticleInfection and immunity2006
In vivo activation of naive CD4+ T cells in nasal mucosa-associated lymphoid tissue following intranasal immunization with recombinant Streptococcus gordonii.
Article in Infection and immunity, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 30 citations in OpenAlex.
- Estradiol Enhances Antiviral CD4Journal of virology · 2020Article
- Xyloglucan based mucosal nanovaccine for immunological protection against brucellosis developed by supercritical fluid technology.International journal of pharmaceutics: X · 2020Article
- Elucidating the Immune-Related Mechanisms by Which Probiotic StrainFrontiers in microbiology · 2018Article
- Heterologous Prime-Boost Combinations Highlight the Crucial Role of Adjuvant in Priming the Immune System.Frontiers in immunology · 2018Article
- Non-invasive administration of biodegradable nano-carrier vaccines.American journal of translational research · 2017Review
- Modulation of Primary Immune Response by Different Vaccine Adjuvants.Frontiers in immunology · 2016Article
- Characterization of the Antigen-Specific CD4(+) T Cell Response Induced by Prime-Boost Strategies with CAF01 and CpG Adjuvants Administered by the Intranasal and Subcutaneous Routes.Frontiers in immunology · 2015Article
- A Stochastic Model for CD4+ T Cell Proliferation and Dissemination Network in Primary Immune Response.PloS one · 2015Article
- CD4(+) T Cell Priming as Biomarker to Study Immune Response to Preventive Vaccines.Frontiers in immunology · 2013Review
- Article
- Prime-boost strategies in mucosal immunization affect local IgA production and the type of th response.Frontiers in immunology · 2013Article
- Probing local innate immune responses after mucosal immunisation.Journal of immune based therapies and vaccines · 2010Article
- Primary activation of antigen-specific naive CD4+ and CD8+ T cells following intranasal vaccination with recombinant bacteria.Infection and immunity · 2008Article
- Stimulation of human monocytes with the gram-positive vaccine vector Streptococcus gordonii.Clinical and vaccine immunology : CVI · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The antigen-specific primary activation of CD4+ T cells was studied in vivo by adoptive transfer of ovalbumin-specific transgenic T cells (KJ1-26+ CD4+) following intranasal immunization with recombinant Streptococcus gordonii. A strain of S. gordonii expressing on its surface a model vaccine antigen fused to the ovalbumin (OVA) peptide from position 323 to 339 was constructed and used to study the OVA-specific T-cell activation in nasal mucosa-associated lymphoid tissue (NALT), lymph nodes, and spleens of mice immunized by the intranasal route. The recombinant strain, but not the wild type, activated the OVA-specific CD4+ T-cell population in the NALT (89% of KJ1-26+ CD4+ T cells) just 3 days following immunization. In the cervical lymph nodes and in the spleen, the percentage of proliferating cells was initially low, but it reached the peak of activation at day 5 (90%). This antigen-specific clonal expansion of KJ1-26+ CD4+ T cells after intranasal immunization was obtained with live and inactivated recombinant bacteria, and it indicates that the NALT is the site of antigen-specific T-cell priming.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.